Evaluation of the Therapeutic Potential of Sulfonyl Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors
Molecules · 26.06.2024 · 29 (13) · 3036
DOI: 10.3390/molecules29133036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 26.06.2024. Verfasst von Biswajit Kundu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section on Medicinal Chemistry, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), 5625 Fishers Lane, R…. Hauptthemen laut MEDLINE: Epoxide Hydrolases, Urea, Enzyme Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, Intramural Research Programs of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), Intramural Research Program of the NIH, National Cancer Institute, CCR.
Abstract (Originalsprache)
The inhibition of soluble epoxide hydrolase (sEH) can reduce the level of dihydroxyeicosatrienoic acids (DHETs) effectively maintaining endogenous epoxyeicosatrienoic acids (EETs) levels, resulting in the amelioration of inflammation and pain. Consequently, the development of sEH inhibitors has been a prominent research area for over two decades. In the present study, we synthesized and evaluated sulfonyl urea derivatives for their potential to inhibit sEH. These compounds underwent extensive in vitro investigation, revealing their potency against human and mouse sEH, with 4f showing the most promising sEH inhibitory potential. When subjected to lipopolysaccharide (LPS)-induced acute lung injury (ALI) in studies in mice, compound 4f manifested promising anti-inflammatory efficacy. We investigated the analgesic efficacy of sEH inhibitor 4f in a murine pain model of tail-flick reflex. These results validate the role of sEH inhibition in inflammatory diseases and pave the way for the rational design and optimization of sEH inhibitors based on a sulfonyl urea template.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section on Medicinal Chemistry, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), 5625 Fishers Lane, Rockville, MD 20852, USA.
- Section on Fibrotic Disorders, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), 5625 Fishers Lane, Rockville, MD 20852, USA.
- Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), P.O. Box B, Frederick, MD 21702, USA.
ORCID-Profile: Abhishek Basu, Lenny Pommerolle, Kyu Ah Kim, Resat Cinar, Malliga R Iyer
Förderung
- NIAAA NIH HHS
- Intramural Research Programs of the National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Intramural Research Program of the NIH, National Cancer Institute, CCR
Zitieren
APA
Kundu, B., Dvorácskó, S., Basu, A., Pommerolle, L., Kim, K. A., Wood, C. M., Gibbs, E., Behee, M., Tarasova, N. I., Cinar, R., & Iyer, M. R. (2024). Evaluation of the Therapeutic Potential of Sulfonyl Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors. Molecules, 29(13), 3036. https://doi.org/10.3390/molecules29133036
Vancouver
Kundu B, Dvorácskó S, Basu A, Pommerolle L, Kim KA, Wood CM, et al. Evaluation of the Therapeutic Potential of Sulfonyl Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors. Molecules. 2024;29(13):3036. doi:10.3390/molecules29133036
BibTeX
@article{Kundu2024,
author = {Kundu, Biswajit and Dvorácskó, Szabolcs and Basu, Abhishek and Pommerolle, Lenny and Kim, Kyu Ah and Wood, Casey M and Gibbs, Eve and Behee, Madeline and Tarasova, Nadya I and Cinar, Resat and Iyer, Malliga R},
title = {Evaluation of the Therapeutic Potential of Sulfonyl Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors},
journal = {Molecules},
year = {2024},
volume = {29},
number = {13},
pages = {3036},
doi = {10.3390/molecules29133036}
}
EUVIMED